| scholarly article | Q13442814 |
| P2093 | author name string | Masanori Abe | |
| Morikazu Onji | |||
| P2860 | cites work | The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 |
| Characterization of antimitochondrial antibodies in health adults | Q46110088 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis | Q47322110 | ||
| Significance of study on prevalence of AMA in healthy subjects | Q47816551 | ||
| Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture | Q47816600 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. | Q50694965 | ||
| Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. | Q53300236 | ||
| Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis | Q57004434 | ||
| Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis | Q58376775 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Familial primary biliary cirrhosis in Hiroshima | Q33707458 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? | Q34190802 | ||
| Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis | Q34394186 | ||
| Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes | Q34445524 | ||
| Portal hypertension in primary biliary cirrhosis | Q34474035 | ||
| Asymptomatic primary biliary cirrhosis | Q34476252 | ||
| Serum bilirubin: a prognostic factor in primary biliary cirrhosis | Q34494336 | ||
| Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis | Q34594429 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| Natural history of primary biliary cirrhosis. | Q35573903 | ||
| Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort | Q35596580 | ||
| Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? | Q35597224 | ||
| Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis | Q35760198 | ||
| Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort | Q35760389 | ||
| Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis | Q40186249 | ||
| Familial primary biliary cirrhosis | Q40634968 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Natural history of early primary biliary cirrhosis | Q41234807 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis | Q43484548 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis | Q45024371 | ||
| Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? | Q45206678 | ||
| P433 | issue | 7 | |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 639-645 | |
| P577 | publication date | 2008-05-06 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Natural history of primary biliary cirrhosis. | |
| P478 | volume | 38 |
| Q53229266 | A case of primary biliary cirrhosis that complicated with combined hepatocellular and cholangiocellular carcinoma. |
| Q92188849 | Abnormal Expression of ERα in Cholangiocytes of Patients With Primary Biliary Cholangitis Mediated Intrahepatic Bile Duct Inflammation |
| Q37855976 | Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis |
| Q50976613 | Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis. |
| Q37449017 | Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report |
| Q46049458 | Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q47550101 | Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma |
| Q34041388 | Primary biliary cirrhosis: What do autoantibodies tell us? |
| Q38162223 | T helper 17 cells in autoimmune liver diseases |
| Q43576890 | Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid. |
Search more.